Menthol 1% in Calamine lotion
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · 1971–2026
Showing the 50 most relevant studies, sorted by most relevant.
Mrinal Gupta, V. Mahajan, K. Mehta, et al.
Dermatology Research and Practice, 2014
P J Aggett, J. Harries
Archives of Disease in Childhood, 1979
Sally Brown, R. Chaney, Angle Jay Scott, et al.
Journal of Environmental Quality, 1994
Hadba Hussain
Nanotechnology and Nanomaterials, 2024
Zinc oxide (ZnO) is a unique material due to its physical and chemical properties, such as wide bandgap at room temperature (RT) (3.37 eV) and high binding energy (60 meV). This chapter contains the most important synthesis methods of doped ZnO nanostructure preparation. The most common methods for preparing nanoparticles (NPs) and thin films (TFs) are sol-gel, precipitation, and hydrothermal. The effects of doping appear in various forms and properties. Therefore, doped ZnO nanostructure characteristics are described to explain the structural properties, including the particle size measurement methods and the other features based on XRD data and others, and optical properties contain the approaches of bandgap energy calculations depending on UV-visible results, as well as electrical and magnetic properties. The doped ZnO nanostructures’ properties change after doping with metals and non-metals. The last part of the chapter illustrates the most prevalent and crucial applications, starting with medicine, followed by photocatalysis, photovoltaic, UV absorbers and photodetectors, and sensors, and finishing with a light-emitting diode (LED). This review provides valuable information when dealing with works related to pure and doped ZnO nanostructures.
Abstract licence: CC BY 3.0
M. Boni, N. Mondillo
Ore Geology Reviews, 2015
M. Boni, D. Large
Economic Geology, 2003
E. Gurgur, S. S. Oluyamo, A. O. Adetuyi, et al.
SN Applied Sciences, 2020
Xiaodong Zhang, Long Chen, Yangbo Sun, et al.
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2018
M. Abedini, F. Shariatmadari, M.A. Karimi Torshizi, et al.
Livestock Science, 2017
Manjula Shantaram, Krishna Kumar M.
International Journal of Research in Dermatology, 2024
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.